Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
作者信息
Schiff Abigail E, Wang Xiaosong, Patel Naomi J, Kawano Yumeko, Hanberg Jennifer L, Kowalski Emily N, Cook Claire E, Vanni Kathleen Mm, Qian Grace, Bade Katarina J, Saavedra Alene A, Srivatsan Shruthi, Williams Zachary K, Venkat Rathnam K, Wallace Zachary S, Sparks Jeffrey A
机构信息
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Ann Rheum Dis. 2024 Apr 11;83(5):680-682. doi: 10.1136/ard-2023-225162.
Abstract
摘要
相似文献
1
Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.类风湿关节炎患者接种第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗后免疫调节剂与突破性新型冠状病毒肺炎（COVID-19）风险：一项队列研究
Ann Rheum Dis. 2024 Apr 11;83(5):680-682. doi: 10.1136/ard-2023-225162.
2
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.接种疫苗和利妥昔单抗治疗的类风湿关节炎患者突破性感染后 SARS-CoV-2 免疫动力学：一项前瞻性队列研究。
Front Immunol. 2024 Feb 22;15:1296273. doi: 10.3389/fimmu.2024.1296273. eCollection 2024.
3
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.免疫应答：类风湿关节炎患者在接受 2 剂灭活或基于载体疫苗基础免疫后未发生血清转阳，接种第 3 剂 SARS-CoV-2 疫苗。
J Rheumatol. 2022 Dec;49(12):1385-1389. doi: 10.3899/jrheum.220469. Epub 2022 Oct 1.
4
Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.BNT162b2 mRNA 疫苗加强针在类风湿关节炎患者 SARS-CoV-2 疫苗接种中的作用。
Immunol Res. 2022 Aug;70(4):493-500. doi: 10.1007/s12026-022-09283-y. Epub 2022 May 11.
5
Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.接种 SARS-CoV-2 疫苗后老年类风湿关节炎患者的抗 S1/RBD 特异性抗体形成：单中心前瞻性观察性研究。
J Korean Med Sci. 2023 Apr 10;38(14):e109. doi: 10.3346/jkms.2023.38.e109.
6
Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis.新型冠状病毒 2 型 mRNA 疫苗对类风湿关节炎关节炎病情的影响。
Front Immunol. 2023 Aug 25;14:1256655. doi: 10.3389/fimmu.2023.1256655. eCollection 2023.
7
Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.接种三剂 SARS-CoV-2 mRNA 疫苗后的细胞和体液免疫应答及突破性感染。
Front Immunol. 2022 Aug 17;13:981350. doi: 10.3389/fimmu.2022.981350. eCollection 2022.
8
Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac.分析利妥昔单抗治疗的类风湿关节炎患者接种联合载体疫苗 Gam-COVID-Vac 后对 SARS-CoV-2 抗原的细胞和体液免疫反应。
Bull Exp Biol Med. 2024 Apr;176(6):786-790. doi: 10.1007/s10517-024-06109-9. Epub 2024 Jun 19.
9
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
10
Impaired Humoral Immunogenicity of SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis.类风湿关节炎患者中 SARS-CoV-2 疫苗接种的体液免疫原性受损。
J Rheumatol. 2022 Jul;49(7):855-858. doi: 10.3899/jrheum.211270. Epub 2022 Feb 1.
引用本文的文献
1
Human tonsil organoids reveal innate pathways modulating humoral and cellular responses to ChAdOx1.人类扁桃体类器官揭示了调节对ChAdOx1体液和细胞反应的固有途径。
PLoS Pathog. 2025 Aug 22;21(8):e1013432. doi: 10.1371/journal.ppat.1013432. eCollection 2025 Aug.
2
COVID-19 vaccine booster uptake and effectiveness among persons with systemic autoimmune and rheumatic diseases.2019冠状病毒病疫苗加强针在患有系统性自身免疫性和风湿性疾病人群中的接种情况及有效性
J Rheumatol. 2025 Aug 1. doi: 10.3899/jrheum.2025-0535.
3
COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of Rituximab.在开始使用利妥昔单抗治疗前接种新冠病毒疫苗可在自身免疫性风湿病中诱导强烈的血清学反应，减轻大流行后对利妥昔单抗影响的担忧。
ACR Open Rheumatol. 2024 Aug;6(8):519-528. doi: 10.1002/acr2.11681. Epub 2024 Jun 23.
4
Characteristics Associated with COVID-19 Breakthrough Infections after Booster Vaccinations in Healthcare Workers: Insights from the TüSeRe:exact Study.医护人员接种加强针后与新冠病毒突破性感染相关的特征：来自TüSeRe:exact研究的见解
J Clin Med. 2024 Mar 9;13(6):1571. doi: 10.3390/jcm13061571.
5
Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology.风湿科生物制剂和靶向合成疾病修正药物的长期安全性。
Curr Opin Rheumatol. 2024 Mar 1;36(2):113-119. doi: 10.1097/BOR.0000000000000995. Epub 2023 Dec 20.
本文引用的文献
1
Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study.与接种疫苗的风湿疾病患者 COVID-19 突破性感染相关的因素：一项队列研究。
Semin Arthritis Rheum. 2023 Feb;58:152108. doi: 10.1016/j.semarthrit.2022.152108. Epub 2022 Oct 26.
2
Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.B 细胞耗竭治疗的免疫介导性疾病患者突破性 SARS-CoV-2 感染：一项回顾性队列分析。
Arthritis Rheumatol. 2022 Dec;74(12):1906-1915. doi: 10.1002/art.42287. Epub 2022 Oct 31.
3
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.使用免疫抑制剂的免疫介导炎症性疾病的接种疫苗患者中出现的德尔塔（B.1.617.2）变异株导致的严重急性呼吸综合征冠状病毒2突破性感染：两项前瞻性队列研究的子研究
Lancet Rheumatol. 2022 Jun;4(6):e417-e429. doi: 10.1016/S2665-9913(22)00102-3. Epub 2022 Apr 29.
4
Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort.接种疫苗后的抗体滴度可预测自身免疫性疾病患者对 COVID-19 的保护作用：前瞻性队列研究中的生存分析。
Ann Rheum Dis. 2022 Jun;81(6):868-874. doi: 10.1136/annrheumdis-2021-221922. Epub 2022 Feb 8.
5
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.美国 SARS-CoV-2 疫苗接种后免疫功能障碍与 COVID-19 突破性感染的关联。
JAMA Intern Med. 2022 Feb 1;182(2):153-162. doi: 10.1001/jamainternmed.2021.7024.
6
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.免疫抑制对SARS-CoV-2 mRNA疫苗免疫原性的影响：一项前瞻性队列研究。
Ann Intern Med. 2021 Nov;174(11):1572-1585. doi: 10.7326/M21-1757. Epub 2021 Aug 31.
Zotero 插件